Comparative Pharmacology
Head-to-head clinical analysis: ALUNBRIG versus CABOMETYX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALUNBRIG versus CABOMETYX.
ALUNBRIG vs CABOMETYX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alunbrig (brigatinib) is a tyrosine kinase inhibitor that targets ALK and ROS1. It inhibits autophosphorylation of ALK and ALK-mediated activation of downstream signaling proteins STAT3, AKT, ERK1/2, and PLCγ in ALK-dependent tumor cells.
Cabozantinib is a small molecule inhibitor of multiple receptor tyrosine kinases, including MET, VEGFR2, RET, AXL, KIT, and FLT3. It inhibits tumor growth, angiogenesis, and metastasis by blocking these pathways.
90 mg orally once daily for first 7 days, then increase to 180 mg orally once daily
60 mg orally once daily for the first 21 days of a 21-day cycle, with or without food, for renal cell carcinoma; for hepatocellular carcinoma, 60 mg orally once daily.
None Documented
None Documented
Terminal half-life approximately 25 hours. Supports once-daily dosing; steady state achieved in ~5 days.
Terminal half-life approximately 99 hours (range 80–120 h). Supports once-daily dosing with steady-state achieved within 15 days.
Primarily hepatic metabolism (CYP3A4); 65% fecal (unchanged and metabolites), 25% renal (1% unchanged). Biliary excretion contributes to fecal elimination.
Primarily fecal (54%) with minimal renal excretion (27% unchanged drug; <10% as metabolites). Biliary excretion contributes to fecal elimination.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor